FDA Screens GLP-1 Ingredients at the Border and Warns of Vials Labeled with Pharmacies That Do Not Exist

What Happened

The U.S. Food and Drug Administration has announced new import screening measures targeting GLP-1 receptor agonists entering the United States through international mail and commercial cargo. The agency is intercepting shipments at ports of entry and testing the contents for identity, purity, and active pharmaceutical ingredient concentration.

In a concurrent alert, the FDA warned healthcare providers and consumers about injectable GLP-1 vials labeled with the names of pharmacies that do not exist. These vials carry pharmacy labels and lot numbers that, when verified, correspond to no licensed pharmacy in any state. The FDA has confirmed multiple cases where the labeled pharmacy is entirely fictitious.

Who Is Affected

The enforcement action affects three groups:

1. Consumers purchasing GLP-1 medications online. Vials sold through non-pharmacy channels may be misbranded, counterfeit, or contain no active ingredient.

2. Research peptide vendors selling GLP-1 compounds. Vendors marketing semaglutide, tirzepatide, retatrutide, or related compounds face increased seizure risk at U.S. ports.

3. Compounding pharmacies. The FDA has previously warned that compounded GLP-1 preparations using non-FDA-approved salt forms are not legally compounded drugs.

Timeline

• August 2026: FDA announces import screening program for GLP-1 ingredients
• September 2026: FDA issues alert about vials with fictitious pharmacy labels
• September 2026: Multiple news outlets report on the enforcement actions
• Ongoing: Border testing continues; seizures reported at multiple ports of entry

What This Means for Researchers

If you purchase research peptides or GLP-1 compounds for laboratory research, the enforcement landscape has changed:

• Shipments may be seized. Import screening means packages containing GLP-1 APIs may be intercepted and tested.
• Vendor reliability matters more than ever. Vendors with verified COA documentation and third-party testing are less likely to be affected.
• COA verification is critical. If you receive GLP-1 vials, verify the COA independently.

How to Verify Your Peptides

PepsReview maintains independent testing resources for the most commonly counterfeited GLP-1 compounds:

• How to Test Semaglutide: Purity and Identity Verification
• How to Test Tirzepatide: HPLC Purity and Identity
• How to Test Retatrutide: HPLC and LC-MS Guide
• Trusted Third-Party Peptide Testing Lab Services

Safe Alternatives: Verified GLP-1 Vendors

Our verified vendor pages include companies with documented COA verification and third-party testing:

• Semaglutide vendor comparison
• Tirzepatide vendor comparison
• Retatrutide guide
• Full vendor directory with P-Scores and COA status for 278+ vendors

FDA Position

The FDA maintains that semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are approved drug products, and that non-FDA-approved versions are unapproved new drugs subject to enforcement. The border screening program represents an escalation from retail-level enforcement to supply-chain-level enforcement.

Sources

• FDA import screening announcement (September 2026)
• FDA alert regarding vials with fictitious pharmacy labels (September 2026)
• Medical Daily coverage
• Yahoo Finance Canada: FDA crackdown on unapproved weight-loss drugs
• TradingView: FDA GLP-1 alert impact on HIMS stock

Stay Updated

This article will be updated as the enforcement situation develops. For real-time updates, bookmark our news page or follow the PepsReview forum.